Início » Publicações » Artigos » Revisões Especiais

Revisões Especiais

Publicação: 18 de dezembro de 2018

– World TB Day 2017: Advances, Challenges and Opportunities in the “End-TB” Era Eskild Petersen, Markus Maeurer, Ben Marais, Giovanni Battista Migliori, Peter Mwaba, Francine Ntoumi, Cris Vilaplana, Kami Kim, Marco Schito, Alimuddin Zumla. p1–5 – Turning the tide against tuberculosis Nesri Padayatchi, Naressa Naidu, Gerald Friedland, Kasavan Naidoo, Francesca Conradie, Kogieleum Naidoo, Max Roe O’Donnell. […]

– World TB Day 2017: Advances, Challenges and Opportunities in the “End-TB” Era

Eskild Petersen, Markus Maeurer, Ben Marais, Giovanni Battista Migliori, Peter Mwaba, Francine Ntoumi, Cris Vilaplana, Kami Kim, Marco Schito, Alimuddin Zumla. p1–5

– Turning the tide against tuberculosis

Nesri Padayatchi, Naressa Naidu, Gerald Friedland, Kasavan Naidoo, Francesca Conradie, Kogieleum Naidoo, Max Roe O’Donnell. p6–9

– Tuberculosis eradication versus control
Marco Schito, Debra Hanna, Alimuddin Zumla. p10–13

– The risk of global epidemic replacement with drug-resistant Mycobacterium tuberculosis strains
Emma S. McBryde, Michael T. Meehan, Tan N. Doan, Romain Ragonnet, Ben J. Marais, Vanina Guernier, James M. Trauer. p14–20

– Funding for tuberculosis research—an urgent crisis of political will, human rights, and global solidarity
Mike Frick. p21–24

– Less research on tuberculosis than HIV and malaria when research agendas are poorly coordinated: a systematic review of research outputs from Cambodia

Mishal Khan, Richard James, Neisha Sundaram, Shishi Wu, Mao Tang Eang, Saphonn Vonthanak, Richard Coker. p25–29

– Shifting from tuberculosis control to elimination: Where are we? What are the variables and limitations? Is it achievable?

Rosella Centis, Lia D’Ambrosio, Alimuddin Zumla, Giovanni Battista Migliori. p30–33

– De-isolation of patients with pulmonary tuberculosis after start of treatment — clear, unequivocal guidelines are missing
Eskild Petersen, Faryal Khamis, Giovanni Battista Migliori, Julie Glerup Bay, Ben Marais, Christian Wejse, Alimuddin Zumla
p34–38

– Tuberculosis associated mortality in a prospective cohort in Sub Saharan Africa: Association with HIV and antiretroviral therapy
Tumaini J. Nagu, Said Aboud, Ramadhani Mwiru, Mecky I. Matee, Martin Rao, Wafaie W. Fawzi, Alimuddin Zumla, Markus J. Maeurer, Ferdinand Mugusi. p39–44

– The global dynamics of diabetes and tuberculosis: the impact of migration and policy implications
Enrico Girardi, Monica Sañé Schepisi, Delia Goletti, Matthew Bates, Peter Mwaba, Dorothy Yeboah-Manu, Francine Ntoumi, Fabrizio Palmieri, Markus Maeurer, Alimuddin Zumla, Giuseppe Ippolito. p45–53

– Tuberculosis and hypertension—a systematic review of the literature
Anneline Borchsenius Seegert, Frauke Rudolf, Christian Wejse, Dinesh Neupane. p54–61

– Health systems in the Republic of Congo: challenges and opportunities for implementing tuberculosis and HIV collaborative service, research, and training activities

Laure Stella Ghoma Linguissi, Luc Christian Gwom, Celine Nguefeu Nkenfou, Matthew Bates, Eskild Petersen, Alimuddin Zumla, Francine Ntoumi. p62–67

– Preventive therapy for latent tuberculosis infection—the promise and the challenges
G.J. Fox, C.C. Dobler, B.J. Marais, J.T. Denholm. p68–76

– Tackling TB in low-incidence countries: improving diagnosis and management in vulnerable populations
C.C. Heuvelings, S.G. de Vries, M.P. Grobusch. p77–80

– Enhanced laboratory capacity development: a boost for effective tuberculosis control in resource-limited settings
Abraham Sunday Alabi, Afsatou Ndama Traoré, Marguerite Massinga Loembe, Ulysse Ateba-Ngoa, Matthias Frank, Ayola Akim Adegnika, Bertrand Lell, Jocelyn Mahoumbou, Carsten Köhler, Peter Gottfried Kremsner, Martin Peter Grobusch, on behalf of the CERMEL TB CapDev Group. p81–84

– European policies in the management of tuberculosis among migrants
Lia D’Ambrosio, Rosella Centis, Masoud Dara, Ivan Solovic, Giorgia Sulis, Alimuddin Zumla, Giovanni Battista Migliori. p85–89

– Tuberculosis stigma as a social determinant of health: a systematic mapping review of research in low incidence countries
G.M. Craig, A. Daftary, N. Engel, S. O’Driscoll, A. Ioannaki. p90–100

– Impact of infectious disease epidemics on tuberculosis diagnostic, management, and prevention services: experiences and lessons from the 2014–2015 Ebola virus disease outbreak in West Africa
Rashid Ansumana, Samuel Keitell, Gregory M.T. Roberts, Francine Ntoumi, Eskild Petersen, Giuseppe Ippolito, Alimuddin Zumla
p101–104

– Evaluating the impact of healthcare provider training to improve tuberculosis management: a systematic review of methods and outcome indicators used
Shishi Wu, Imara Roychowdhury, Mishal Khan. p105–110

– Quality of tuberculosis care in high burden countries: the urgent need to address gaps in the care cascade
Danielle Cazabon, Hannah Alsdurf, Srinath Satyanarayana, Ruvandhi Nathavitharana, Ramnath Subbaraman, Amrita Daftary, Madhukar Pai. p111–116

– Status of Tuberculosis services in Indian Prisons
Banuru Muralidhara Prasad, Badri Thapa, Sarabjit Singh Chadha, Anand Das, Entoor Ramachandra Babu, Subrat Mohanty, Sripriya Pandurangan, Jamhoih Tonsing. p117–121

– Improving access to tuberculosis preventive therapy and treatment for children
Ben J. Marais. p122–125

– Learning from epidemiological, clinical, and immunological studies on Mycobacterium africanum for improving current understanding of host–pathogen interactions, and for the development and evaluation of diagnostics, host-directed therapies, and vaccines for tuberculosis

Alimuddin Zumla, Isaac Darko Otchere, Gloria Ivy Mensah, Adwoa Asante-Poku, Florian Gehre, Markus Maeurer, Matthew Bates, Peter Mwaba, Francine Ntoumi, Dorothy Yeboah-Manu. p126–129

– Removing the bottleneck in whole genome sequencing of Mycobacterium tuberculosis for rapid drug resistance analysis: a call to action
Ruth McNerney, Taane G. Clark, Susana Campino, Camilla Rodrigues, David Dolinger, Liezel Smith, Andrea M. Cabibbe, Keertan Dheda, Marco Schito. p130–135

– Strong anti-Epstein Barr virus (EBV) or cytomegalovirus (CMV) cellular immune responses predict survival and a favourable response to anti-tuberculosis therapy
Tumaini Nagu, Said Aboud, Martin Rao, Mecky Matee, Rebecca Axelsson, Davide Valentini, Ferdinand Mugusi, Alimuddin Zumla, Markus Maeurer. p136–139

– Peptide microarray-based characterization of antibody responses to host proteins after bacille Calmette–Guérin vaccination
Davide Valentini, Martin Rao, Lalit Rane, Sayma Rahman, Rebecca Axelsson-Robertson, Rainer Heuchel, Matthias Löhr, Daniel Hoft, Susanna Brighenti, Alimuddin Zumla, Markus Maeurer. p140–154

– Immune recognition surface construction of Mycobacterium tuberculosis epitope-specific antibody responses in tuberculosis patients identified by peptide microarrays
Davide Valentini, Martin Rao, Giovanni Ferrara, Marc Perkins, Ernest Dodoo, Alimuddin Zumla, Markus Maeurer. p155–166

– Humoral immune profiling of mycobacterial antigen recognition in sarcoidosis and Löfgren’s syndrome using high-content peptide microarrays
Giovanni Ferrara, Davide Valentini, Martin Rao, Jan Wahlström, Johan Grunewald, Lars-Olof Larsson, Susanna Brighenti, Ernest Dodoo, Alimuddin Zumla, Markus Maeurer. p167–175

– Insights gained from ancient biomolecules into past and present tuberculosis—a personal perspective
Helen D. Donoghue. p176–180

– Classifying new anti-tuberculosis drugs: rationale and future perspectives
Simon Tiberi, Anna Scardigli, Rosella Centis, Lia D’Ambrosio, Marcela Muñoz-Torrico, Miguel Ángel Salazar-Lezama, Antonio Spanevello, Dina Visca, Alimuddin Zumla, Giovanni Battista Migliori, Jose A. Caminero Luna. p181–184

– Second line drug susceptibility testing to inform the treatment of rifampin-resistant tuberculosis: a quantitative perspective
Emily A. Kendall, Ted Cohen, Carole D. Mitnick, David W. Dowdy. p185–189

– Applicability of the shorter ‘Bangladesh regimen’ in high multidrug-resistant tuberculosis settings
Giovanni Sotgiu, Simon Tiberi, Rosella Centis, Lia D’Ambrosio, Zhenia Fuentes, Alimuddin Zumla, Giovanni Battista Migliori
p190–193

– Pediatric multidrug-resistant tuberculosis clinical trials: challenges and opportunities
S.E. McAnaw, A.C. Hesseling, J.A. Seddon, K.E. Dooley, A.J. Garcia-Prats, S. Kim, H.E. Jenkins, H.S. Schaaf, T.R. Sterling, C.R. Horsburgh. p194–199

– Retrospective study of clinical and lesion characteristics of patients undergoing surgical treatment for Pulmonary Tuberculosis in GeorgiaSergo Vashakidze, Albert Despuig, Shota Gogishvili, Keti Nikolaishvili, Natalia Shubladze, Zaza Avaliani, Nestan Tukvadze, Martí Casals, Joan A. Caylà, Pere-Joan Cardona, Cristina Vilaplana. p200–207

– Advancing tuberculosis drug regimen development through innovative quantitative translational pharmacology methods and approaches

Debra Hanna, Klaus Romero, Marco Schito. p208–211

– New tuberculosis drug leads from naturally occurring compounds
Diana Quan, Gayathri Nagalingam, Richard Payne, James A. Triccas. p212–220

– Anti-PD-1/PD-L1 therapy for infectious diseases: learning from the cancer paradigm
Martin Rao, Davide Valentini, Ernest Dodoo, Alimuddin Zumla, Markus Maeurer. p221–228

– Ultrasound for patients in a high HIV/tuberculosis prevalence setting: a needs assessment and review of focused applications for Sub-Saharan Africa
Tom Heller, Eric A. Mtemang’ombe, Michaëla A.M. Huson, Charlotte C. Heuvelings, Sabine Bélard, Saskia Janssen, Sam Phiri, Martin P. Grobusch. p229–236

– Imaging in extrapulmonary tuberculosis
Sanjay Gambhir, Mudalsha Ravina, Kasturi Rangan, Manish Dixit, Sukanta Barai, Jamshed Bomanji, the International Atomic Energy Agency Extra-pulmonary TB Consortium. p237–247

– Exploring tuberculosis by molecular tests on DNA isolated from smear microscopy slides
Niaina Rakotosamimanana, Marie Sylvianne Rabodoarivelo, Juan Carlos Palomino, Anandi Martin, Voahangy Rasolofo Razanamparany. p248–252

– A tuberculosis biomarker database: the key to novel TB diagnostics
Seda Yerlikaya, Tobias Broger, Emily MacLean, Madhukar Pai, Claudia M. Denkinger. p253–257

– High-throughput and computational approaches for diagnostic and prognostic host tuberculosis biomarkers
January Weiner, Stefan H.E. Kaufmann. p258–262

– Novel approaches to tuberculosis vaccine development
Stefan H.E. Kaufmann, January Weiner, C. Fordham von Reyn. p263–267

– Experimental animal modelling for TB vaccine development
Pere-Joan Cardona, Ann Williams. p268–273

– Mycobacterium tuberculosis proteins involved in cell wall lipid biosynthesis improve BCG vaccine efficacy in a murine TB model
Martin Rao, Nathalie Cadieux, Megan Fitzpatrick, Steven Reed, Sergei Arsenian, Davide Valentini, Shreemanta Parida, Ernest Dodoo, Alimuddin Zumla, Markus Maeurer. p274–282

– A literary approach to tuberculosis: lessons learned from Anton Chekhov, Franz Kafka, and Katherine Mansfield
Cristina Vilaplana. p283–285

PDF: Alabi_Int_J_Infect_Dis_2017

PDF: Ansumana_Int_J_Infect_Dis_2017

PDF: Cardona_Int_J_Infect_Dis_2017

PDF: Cazabon_Int_J_Infect_Dis_2017

PDF: Centis_Int_J_Infect_Dis_2017

PDF: Craig_Int_J_Infect_Dis_2017